España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
NYLI Healthy Hearts ETF
HART
ARCA
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$31.14
-0.00200
-0.01%
At close: -
Get Report
Comment
Overview
News
Holdings
Dividends
Short Interest
Latest news for NYLI Healthy Hearts ETF (ARCA:HART)
NYLI Healthy Hearts ETF (ARCA: HART)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, April 11, 2024
Nike Bets On Olympics to Boost Performance Sales: Report
Lekha Gupta
Friday, December 29, 2023
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
Vandana Singh
Thursday, March 17, 2016
Harvard Apparatus Regenerative Technology Rep...
Benzinga
Thursday, March 10, 2016
HART Announced Fr. Blaine McKee To Co Board
Benzinga
Thursday, January 07, 2016
HART and Mayo Clinic Confirm Dates for Collaborative Large-Animal Bioengineered Organ Implant Surgeries
Benzinga
Tuesday, December 29, 2015
Filing from Harvard Apparatus Regenerative Te...
Benzinga
Tuesday, December 15, 2015
UPDATE: HART Says Deal with Aspire Capital fo...
Benzinga
Harvard Apparatus Regenerative Tech Reports S...
Benzinga
Tuesday, December 01, 2015
Morning Market Losers
Benzinga
Monday, November 30, 2015
HART Regains Compliance With Nasdaq Minimum Bid Price Listing Rule
Benzinga
Harvard Apparatus +32% @$2.91; Co Presenting ...
Benzinga
Tuesday, November 17, 2015
Harvard Apparatus Regenerative CFO McNaughton...
Benzinga
Thursday, November 12, 2015
HART Reports Q3 EPS ($0.19) vs. Prior Year Qu...
Benzinga
Harvard Apparatus Regenerative Tech Up ~42% F...
Benzinga
Thursday, August 13, 2015
Harvard Apparatus Regenerative Technology Rep...
Benzinga
Thursday, April 16, 2015
Harvard Apparatus Reports David Green Resigns...
Benzinga
Thursday, February 12, 2015
Morning Market Gainers
Benzinga
Harvard Apparatus Reports Pricing of 1.8M Sha...
Benzinga
Wednesday, February 11, 2015
Harvard Apparatus Regenerative Technology Ann...
Benzinga
Wednesday, January 07, 2015
HART, Mayo Clinic Report Collaboration Relate...
Benzinga
Friday, October 17, 2014
Harvard Apparatus Regenerative Technology Updates Patient Status
Benzinga
Friday, September 05, 2014
Harvard Apparatus Regenerative Technology Obtains Orphan Drug Designation From U.S. Food And Drug Administration For HART-Trachea
Benzinga
Friday, August 08, 2014
Harvard Apparatus Regenerative Technology Rea...
Benzinga
Harvard Apparatus Regenerative Technology Reports Q2 EPS of $(0.32) vs $(0.27) Est
Benzinga
Thursday, May 08, 2014
Harvard Apparatus Regenerative Technology Reports Q1 EPS of $(0.39) vs $(0.33) Est
Benzinga
Thursday, April 10, 2014
Summer Street Started Coverage on Harvard Apparatus Regenerative Technology at Buy, Shares Holding Onto Positive Territory
Benzinga
Monday, March 31, 2014
Harvard Apparatus Regenerative Technology Sha...
Benzinga
Shares of Harvard Apparatus Regenerative Technology Rise 6%; May be Attributed to Presentation Posted on Co Website
Benzinga
Friday, March 14, 2014
Benzinga's Volume Movers
Benzinga
Maxim Group Initiates Coverage on Harvard Apparatus Regenerative Technology at Buy, Announces $19.00 PT
Benzinga
Harvard Apparatus Regenerative Technology Shares Rise 21% Premarket on Investor Presentation; Analyst Buy Rating
Benzinga
